Technical outlook – Approaching this share from a technical perspective, the current market pattern is nesting on a support base at $1.20 -$1.30.
After assessing the extent of the sell-off at the beginning of July 2020, we believe the bullish pathway is expected to unfold towards the recent highs of $1.60-70
Company Overview – Telix Pharmaceuticals Limited (TLX) is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation.
TLX is headquartered in Melbourne with international operations in Brussels, Kyoto and Indianapolis.
TLX is developing a portfolio of clinical-stage oncology products that address a significant unmet medical need in renal, prostate and brain (glioblastoma) cancer.